Multimodal Machine Learning Characterization of Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Adenocarcinoma of Prostate
- Glioma
- Hepatocellular Carcinoma (HCC)
- Prostate Cancer
- Radical Prostatectomy
- Renal Cell Carcinoma (RCC)
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is an observational imaging study to evaluate the value of multimodal [18F]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI) for solid tumor characterization and disease staging. This research study involves: Screening visit, and 1-3 study Multimodal [18F]DCFPyL PET/M...
This is an observational imaging study to evaluate the value of multimodal [18F]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI) for solid tumor characterization and disease staging. This research study involves: Screening visit, and 1-3 study Multimodal [18F]DCFPyL PET/MRI visits Two cohorts of participants will be enrolled in this study: primary prostate cancer patients and patients with known or suspected solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma) It is expected that about 135 people will take part in this research study The PET dye used in this study is called [18F]DCFPyL. [18F]DCFPyL is not approved by the U.S. Food and Drug administration (FDA). This means [18F]DCFPyL can only be used in research studies. The PET/MRI scanner was approved by the U.S. FDA.
Tracking Information
- NCT #
- NCT04687969
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Ciprian Catana, MD, Ph.D Massachusetts General Hospital
Get Well Soon